News

News 29.10.2018 Zurich-Schlieren, October 29, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in...

News 24.10.2018 Schlieren (Zurich), Switzerland, October 22, 2018 – Kuros Biosciences AG (SIX: KURN) announced that its Dutch subsidiary, Kuros Biosciences BV, has recently been granted the US patent, US 10’064’892, entitled “Method for producing an osteoinductive calcium phosphate and products thus obtained” by the United States Patent and Trademark Office (USPTO). The patent covers...

Internal events
Event date: 06.11.2018 The expert from Morgan Sindall, Dr. Xavier Casadevall i Solvas, will review several applications of Microtechnology and in particular of Microfluidics. He will place special emphasis on how it can be harnessed to obtain biological information at superior levels of both quality and throughput, and how it can be used to...

Internal events
Event date: 06.11.2018 If you'd like to discuss your current challenges with experts, Morgan Sindall is offering you the opportunity of a free consultation exchange. Profit from the chance to discuss your business needs with a Morgan Sindall expert without any obligations. The following topics will be approached: Clinical evaluations Regulatory affairs for medicinal products...

External events
Event date: 23.10.2018 Dienstag, 23. Oktober 2018, 16.30 bis 21.00 Uhr IFAS 2018, Messe Zürich Die neuen MDR-/IVDR-Regulierungen stellen die gesamte Medtech-Industrie vor eine grosse operative und strategische Herausforderung, deren Auswirkungen den Geschäftsgang vieler Unternehmen – insbesondere von KMUs – stark beeinträchtigen werden. Diese Veranstaltung, die im Rahmen der IFAS 2018 stattfindet, bringt führende Experten...